相关实验视频

Updated: May 9, 2025

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

分析HPV独立和HPV相关的宫腺癌之间的差异

Jing He¹, Gulixian Tu Lu Weng Jiang², Lin Zeng¹

¹Department of Pathology, The Third Hospital of Mianyang, Mianyang, China.

Frontiers in oncology

|May 2, 2025

概括

人类乳头瘤病毒 (HPV) 独立的宫腺癌 (HPV-Ind-CA) 的预后比与HPV相关的宫腺癌 (HPV-CA) 更差. 识别特定的风险因素,如CA125和CA199水平升高,可以指导加强治疗以获得更好的结果.

科学领域:

妇科瘤学妇科瘤学
病理学病理学病理学
癌症研究癌症研究

背景情况:

缺少与HPV相关的宫腺癌 (HPV-CA) 和HPV独立的宫腺癌 (HPV-Ind-CA) 的预后评估标准.
了解临床病理特征和生存的差异对于有效的临床管理至关重要.

研究的目的:

为了比较HPV-CA和HPV-Ind-CA患者之间的临床病理特征和生存预后.
确定宫腺癌的预后因素,以改善诊断,治疗和患者的治疗结果.

主要方法:

在2012年至2023年期间诊断的47名HPV-Ind-CA和285名HPV-CA患者的回顾性分析.
临床特征,瘤标志物 (CEA,CA125,CA199),HPV状态,治疗方案和病理结果的比较.
通过追踪到2023年7月,评估治疗疗效和生存结果 (PFS,OS).

主要成果:

与HPV-CA患者相比,HPV-Ind-CA患者年龄较大,差异化较低,FIGO阶段较晚,CA125水平较高.
与HPV-CA组 (26和35个月) 相比,HPV-Ind-CA组 (12和21个月) 的PFS和OS中位数显著较短.
在HPV-Ind-CA中,OS的独立预后因素包括低分化和高CA199;在HPV-CA中,它们包括FIGO阶段,没有HPV,高CA125,年龄较大和高CA199.

结论:

与HPV-CA相比,HPV-Ind-CA与较低的临床病理特征和生存结果有关.
较高的CA125和CA199水平,较晚的FIGO阶段和HPV阴性是预后较差的关键指标.
对于HPV阴性患者,瘤标志物升高和晚期患者,应考虑加强治疗方案,以改善存活率.

关键词:

不依赖于HPV的宫腺癌与HPV相关的宫腺癌.宫腺癌的发生预后预后预后这是一项回顾性队列研究.

更多相关视频

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...